Evidence map›Paper›PMID 41802134›Full record

ArticleKidney & blood pressure research2026

Ten-Year Results of Therapeutic Intravascular Ultrasound Renal Denervation in Resistant Hypertension: A Prospective Single-Center Study.

Michael Jonas, Omar Ayyad, Mohammad Alnees, Alena Kirzhner, Tal Schiller, Christian Spaulding, Abdalaziz Darwish, Ameer Mahamid, Ortal Tuvali, Adam Hassan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael JonasHeart Center, Kaplan Medical Center, Rehovot, Israel.
Omar AyyadHeart Center, Kaplan Medical Center, Rehovot, Israel.
Mohammad AlneesHarvard Medical School, Postgraduate Medical Education, Global Clinical Scholar Research Training Program, Boston, Massachusetts, USA.
Alena KirzhnerDepartment of Internal Medicine A, Kaplan Medical Center, Rehovot, Israel.
Tal SchillerDepartment of Diabetes, Endocrinology and Metabolism, Kaplan Medical Center, Rehovot, Israel.
Christian SpauldingCardiology Department, CIC 1418, European Hospital Georges Pompidou, Assistance Publique Hôpitaux de Paris, and Université Paris Cité, INSERM, PARCC, Paris, France.
Abdalaziz DarwishDepartment of Internal Medicine B, Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ameer MahamidDepartment of Internal Medicine B, Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ortal TuvaliHeart Center, Kaplan Medical Center, Rehovot, Israel.
Adam HassanDepartment of Internal Medicine B, Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Haitham Abu KhadijaHeart Center, Kaplan Medical Center, Rehovot, Israel, haitham2048@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRenal denervation (RDN) is an emerging therapy for resistant hypertension. The therapeutic intravascular ultrasound (TIVUS) system offers a nonocclusive, multidirectional approach, but its long-term efficacy and safety remain unknown.

methodsWe prospectively followed 12 patients with severe resistant hypertension who underwent bilateral ultrasound RDN as part of the TIVUS trial. Office BP was measured at baseline, 1, 3, 6, and 12 months; 24-h ambulatory BP at years 1, 2, 5, and 10. Estimated glomerular filtration rate (eGFR) and adverse events were tracked. BP changes were analyzed using mixed-effects models adjusted for baseline covariates.

resultsMean age was 65 ± 8 years; 75% had diabetes. Baseline office BP averaged 176/84 mm Hg. The procedure was completed in all patients without complications. Systolic office BP decreased by 22.1 mm Hg at 1 month and 36.2 mm Hg at 12 months (both p < 0.001). At 10 years, office BP reductions were -38.6/-13.3 mm Hg (p < 0.001). Ambulatory BP declined from 149.4 ± 9.8 to 128.4 ± 10.0 mm Hg (ASBP) and from 85.0 ± 8.5 to 74.4 ± 9.2 mm Hg (ADBP). The 10-year change in antihypertensive defined daily doses was -1.70 (95% CI -2.75 to -0.38; p = 0.002). eGFR declined modestly (68.6 to 60.2 mL/min/1.73 m2), consistent with aging. No procedure-related adverse events occurred.

conclusionTIVUS ultrasound RDN achieved durable BP reduction with preserved renal function over 10 years.

Indexed as

HypertensionKidneyUltrasonography, InterventionalAgedBlood PressureFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAmbulatory blood pressure monitoringLong-term outcomesRenal denervationResistant hypertensionTherapeutic intravascular ultrasound

Identifiers

PMID41802134
PMCPMC13186550

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.